Market & You
Open in Telegram
SEBI Mandatory Guidelines Group Disclaimer/ disclosures 👉This group do not provide any tips/recommendations/advice/paid advisory services. 👉This group may or may not have SEBI regitered advisors. 👉All updates/posts/discussions are only for educational
Show more517
Subscribers
No data24 hours
-27 days
-630 days
Posts Archive
517
Deepak Ntr
CMP: 1740 Good to add till 1700
Weak below : 1670
Upside potential: 1870-1900
Disclaimer: Holding from lower levels
517
POLYCAB INDIA: Q1 CONS NET PROFIT 7.8B RUPEES VS 5.9B (YOY); EST 7.13B
POLYCAB INDIA: Q1 EBITDA 11.36B RUPEES VS 8.58B (YOY); EST 10.6B || Q1 EBITDA MARGIN 13.84% VS 14.52% (YOY); EST 13.4%
POLYCAB INDIA: Q1 REVENUE 82.1B RUPEES VS 59B (YOY); EST 79.02B
517
ITC HOTELS: Q1 CONS NET PROFIT 1.8B RUPEES VS 1.33B (YOY)
ITC HOTELS: Q1 REVENUE 9.4B RUPEES VS 8.2B (YOY)
ITC HOTELS: Q1 EBITDA 2.96B RUPEES VS 2.48B (YOY) || Q1 EBITDA MARGIN 31.62% VS 30.5% (YOY)
517
Glenmark pharma
CMP: 2225
Good to add till 2150-2180
Weak below : Daily close below 2130
Upside potential: 2380, 2450+
517
Minda Corp (Weekly) Range Breakout
CMP: 664 dips can be accumulated till 630-640
Upside potential 710, 750
View invalid below a weekly close below 620
Disclaimer: Part of my portfolio
Not a Buy sell recommendation, DYOR
517
Mankind pharma
CMP: 2320
Good to add till 2260
Upside potential: 2450, 2500 & 2600+
View invalid below : 2200
Do your own Research not a Buy sell recommendation
517
DEEPAK FERTILISERS Q4 CONSOLIDATED RESULTS 📊
• Net Profit ₹139.39 Cr ↓ 49.8% YoY, ↓ 1.5% QoQ
• Revenue ₹3,011.38 Cr ↑ 12.9% YoY, ↑ 6.4% QoQ
• EBITDA ₹353.99 Cr ↓ 26.3% YoY, ↑ 0.2% QoQ
• Margins 11.75% vs 18.00% YoY, 12.48% QoQ ↓
• Dividend ₹10/share announced
